Black Friday Sale! Save huge on InvestingProGet up to 60% off

Dollar Heads South Amid Vaccine, Stimulus Optimism

Published 12/03/2020, 02:58 AM
Updated 12/03/2020, 03:00 AM
© Reuters.
EUR/USD
-
GBP/USD
-
USD/JPY
-
AUD/USD
-
PFE
-

By Peter Nurse

Investing.com - The dollar continues to lack friends in early European trade Thursday, with optimism over the rollout of vaccines and talk of new U.S. fiscal stimulus prompting risk-on trades.

At 3:55 AM ET (0755 GMT), the Dollar Index, which tracks the greenback against a basket of six other currencies, was down 0.2% at 90.925, trading around levels last seen well over two years ago.

EUR/USD climbed 0.1% to 1.2124, at levels not seen since April 2018, even with the European Central Bank widely expected to enhance its quantitative easing next week. 

USD/JPY fell 0.1% to 104.38, while the risk-sensitive AUD/USD climbed 0.2% to 0.7428, its highest level in more than two years.

Optimism over U.S. stimulus talks and bets on a successful roll-out of vaccines are leading traders to take bets on global growth and thus riskier currencies at the expense of the safe haven dollar, the world’s reserve currency, particularly with the Federal Reserve committed to keeping rates low for years.

This move lower in the dollar has occurred despite the latest employment data showing a slowdown in the jobs recovery, with Wednesday’s monthly ADP report showing private payrolls grew at their slowest pace since July in November.

Weekly initial jobless claims data will be studied later Thursday to see if they provide a similar picture ahead of Friday’s official employment report.

“Data is clearly playing second fiddle to vaccine and stimulus news. Markets may retain an upbeat stance on the latter for now as bipartisan talks resume, providing further support to risk assets and reinforcing the bearish dollar argument,” said analysts at ING, in a research note.

Elsewhere, GBP/USD gained 0.2% to $1.3385, remaining close to a three-month high. Sterling received a boost Wednesday as the U.K. approved a Covid-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech and said it would start vaccinating those most at risk early next week. However, the focus remains on the Brexit trade deal talks.

France warned Wednesday it could veto a trade deal between the U.K. and the European Union if it doesn’t like the terms of the deal, an intervention that puts pressure on EU negotiator Michel Barnier not to give too much ground.

Over the past month, the number of short bets against sterling has increased, according to data by the U.S. Commodity Futures Trading Commission, suggesting the downside potential is quite large, should the two sides fail to agree a deal.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.